• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Beta Bionics appoints new CMO as it prepares for artificial pancreas launch

January 9, 2023 By Sean Whooley

Dr. Steven Russell Beta Bionics
Dr. Steven Russell. [Image courtesy of Beta Bionics]
Beta Bionics announced that it appointed Dr. Steven Russell as its chief medical officer (CMO) as it readies itself for a major product launch.

Concord, Massachusetts-based Beta Bionics develops the iLet bionic pancreas system. The pocket-sized, wearable, investigational iLet device autonomously doses insulin. Worn like an insulin pump, iLet users only enter body weight to initialize therapy. Users would no longer have the need for insulin regimen parameters.

The company designed the device to then automatically titrate and infuse insulin. It eliminates the requirement of counting carbs, the settings of certain rates and factors and more. Former Beta Bionics interim CEO and board member Martha Aronson spoke to Drug Delivery Business News least year. She said iLet could help those with diabetes reduce the cognitive burden of managing their disease.

“As we move closer to commercial launch of the iLet Bionic Pancreas, we have strategically added a wealth of knowledge and experience to our executive team,” said Sean Saint, president and CEO of Beta Bionics.  “Dr. Russell is one of the foremost thought leaders in the field of diabetes technology and I have turned to him often over the years for his expertise and perspective. His experience with the bionic pancreas in a clinical setting is second to none. There is no better person we could have for our Chief Medical Officer as we complete the regulatory review process and prepare for the US launch of the iLet.”

About new Beta Bionics CMO Dr. Steven Russell

Russell, an endocrinologist and diabetologist, brings 20 years of experience in diabetes management. He serves as an associate professor of medicine at Harvard Medical School. He also works as an attending physician at Massachusetts General Hospital Diabetes Associates.

His work at MGH centers around the application of new technologies to improve the care of people with diabetes. That includes work with Beta Bionics founder and executive chair Dr. Ed Damiano’s Boston University research group. That group aims to develop and test a wearable bionic pancreas for automated blood glucose control in diabetes.

“The bionic pancreas project has been the focus of my professional life for many years,” said Russell. “Until the completion of the pivotal trial, I felt I was able to bring the most value to the project as an academic physician, providing advice and executing clinical trials. Now that the pivotal trial is complete, I think my contributions will be most impactful by providing medical leadership within Beta Bionics as we work to obtain FDA clearance and prepare for the launch of the iLet.”

Russell plans to retain his Harvard Medical School faculty appointment. Additionally, he remains at MGH Diabetes Associates on a part-time basis.

“I am thrilled to welcome Steven to Beta Bionics as our new chief medical officer,” said Damiano. “I began collaborating with Steven on the bionic pancreas project over 15 years ago. Our partnership has spanned inpatient clinical trials, pre-pivotal home-use clinical trials, and most recently, a pivotal trial of the iLet in adults and children with type 1 diabetes. Simply put, the bionic pancreas would not be as far along as it is today without Steven Russell.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Personnel Tagged With: Beta Bionics, personn

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS